Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August 2020 in France was conducted. Clinical characteristics were collected at initiation and at 1 and 3 months. Safety and effectiveness were evaluated by September 2020. National-level transplantation and mortality figures for 2020 were obtained from the French CF and transplant centers and registries. Measurements and Main Results: Elexacaftor-tezacaftor- ivacaftor was initiated in 245 patients with a median (interquartile range) ppFEV1 = 29 (24-34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended.
| Errataetall: |
CommentIn: Am J Respir Crit Care Med. 2021 Aug 1;204(3):372-374. - PMID 33951399 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:204 |
|---|---|
| Enthalten in: |
American journal of respiratory and critical care medicine - 204(2021), 1 vom: 01. Juli, Seite 64-73 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Burgel, Pierre-Régis [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.09.2021 Date Revised 13.09.2021 published: Print CommentIn: Am J Respir Crit Care Med. 2021 Aug 1;204(3):372-374. - PMID 33951399 Citation Status MEDLINE |
|---|
| doi: |
10.1164/rccm.202011-4153OC |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321595416 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321595416 | ||
| 003 | DE-627 | ||
| 005 | 20231225180148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.202011-4153OC |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321595416 | ||
| 035 | |a (NLM)33600738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Burgel, Pierre-Régis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2021 | ||
| 500 | |a Date Revised 13.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Am J Respir Crit Care Med. 2021 Aug 1;204(3):372-374. - PMID 33951399 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August 2020 in France was conducted. Clinical characteristics were collected at initiation and at 1 and 3 months. Safety and effectiveness were evaluated by September 2020. National-level transplantation and mortality figures for 2020 were obtained from the French CF and transplant centers and registries. Measurements and Main Results: Elexacaftor-tezacaftor- ivacaftor was initiated in 245 patients with a median (interquartile range) ppFEV1 = 29 (24-34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a cystic fibrosis transmembrane conductance regulator modulators | |
| 650 | 4 | |a elexacaftor | |
| 650 | 4 | |a lung transplantation | |
| 650 | 7 | |a Aminophenols |2 NLM | |
| 650 | 7 | |a Chloride Channel Agonists |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 700 | 1 | |a Durieu, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Chiron, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Ramel, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Danner-Boucher, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Prevotat, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Grenet, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Marguet, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Reynaud-Gaubert, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Macey, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Mely, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Fanton, Annlyse |e verfasserin |4 aut | |
| 700 | 1 | |a Quetant, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Lemonnier, Lydie |e verfasserin |4 aut | |
| 700 | 1 | |a Paillasseur, Jean-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Da Silva, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Clémence |e verfasserin |4 aut | |
| 700 | 0 | |a French Cystic Fibrosis Reference Network Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Andrejak, Claire |e investigator |4 oth | |
| 700 | 1 | |a Becourt, Arnaud |e investigator |4 oth | |
| 700 | 1 | |a Mounard, Julie |e investigator |4 oth | |
| 700 | 1 | |a Poulet, Claire |e investigator |4 oth | |
| 700 | 1 | |a Rames, Cinthia |e investigator |4 oth | |
| 700 | 1 | |a Talleux, Marie |e investigator |4 oth | |
| 700 | 1 | |a Chevalier, Marie-Chantal |e investigator |4 oth | |
| 700 | 1 | |a Darviot, Estelle |e investigator |4 oth | |
| 700 | 1 | |a Jouvenot, Marie |e investigator |4 oth | |
| 700 | 1 | |a Marien, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Paris, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Pelatan, Cécile |e investigator |4 oth | |
| 700 | 1 | |a Person, Christine |e investigator |4 oth | |
| 700 | 1 | |a Priou, Pascaline |e investigator |4 oth | |
| 700 | 1 | |a Troussier, Françoise |e investigator |4 oth | |
| 700 | 1 | |a Urban, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Dalphin, Marie-Laure |e investigator |4 oth | |
| 700 | 1 | |a Dalphin, Jean-Charles |e investigator |4 oth | |
| 700 | 1 | |a Ladaurade, Alice |e investigator |4 oth | |
| 700 | 1 | |a Pernet, Didier |e investigator |4 oth | |
| 700 | 1 | |a Richaud-Thiriez, Bénédicte |e investigator |4 oth | |
| 700 | 1 | |a Roux-Claude, Pauline |e investigator |4 oth | |
| 700 | 1 | |a Blanc, Nathalia |e investigator |4 oth | |
| 700 | 1 | |a Boisserie-Lacroix, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Bui, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Collet, Cyrielle |e investigator |4 oth | |
| 700 | 1 | |a Debelleix, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a Macey, Julie |e investigator |4 oth | |
| 700 | 1 | |a Bergot, Emmanuel |e investigator |4 oth | |
| 700 | 1 | |a Brouard, Jacques |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Karine |e investigator |4 oth | |
| 700 | 1 | |a Laurans, Muriel |e investigator |4 oth | |
| 700 | 1 | |a Ribault, Virginie |e investigator |4 oth | |
| 700 | 1 | |a Borderon, Corinne |e investigator |4 oth | |
| 700 | 1 | |a Heraud, Marie-Christine |e investigator |4 oth | |
| 700 | 1 | |a Labbe, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Montcouquiol, Sylvie |e investigator |4 oth | |
| 700 | 1 | |a Petit, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Ruivard, Marc |e investigator |4 oth | |
| 700 | 1 | |a Delestrain, Céline |e investigator |4 oth | |
| 700 | 1 | |a Douvry, Benoit |e investigator |4 oth | |
| 700 | 1 | |a Epaud, Ralph |e investigator |4 oth | |
| 700 | 1 | |a Maitre, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Remus, Natascha |e investigator |4 oth | |
| 700 | 1 | |a Beltramo, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Fanton, Annlyse |e investigator |4 oth | |
| 700 | 1 | |a Houzel, Anne |e investigator |4 oth | |
| 700 | 1 | |a Huet, Frédéric |e investigator |4 oth | |
| 700 | 1 | |a Perez, Stéphanie |e investigator |4 oth | |
| 700 | 1 | |a Boldron-Ghaddar, Amale |e investigator |4 oth | |
| 700 | 1 | |a Scalbert, Manuela |e investigator |4 oth | |
| 700 | 1 | |a Bouzioukh, Rabah |e investigator |4 oth | |
| 700 | 1 | |a Mely, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Simon, Charles |e investigator |4 oth | |
| 700 | 1 | |a Camara, Boubou |e investigator |4 oth | |
| 700 | 1 | |a Hamidfar, Rébecca |e investigator |4 oth | |
| 700 | 1 | |a Llerena, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Pin, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Quetant, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Deschildre, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Gicquello, Alice |e investigator |4 oth | |
| 700 | 1 | |a Le Rouzic, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Leroy, Clara |e investigator |4 oth | |
| 700 | 1 | |a Paris, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Perez, Thierry |e investigator |4 oth | |
| 700 | 1 | |a Prevotat, Anne |e investigator |4 oth | |
| 700 | 1 | |a Thumerelle, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Turck, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Wizla, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Dupuy-Grasset, Magali |e investigator |4 oth | |
| 700 | 1 | |a Languepin, Jane |e investigator |4 oth | |
| 700 | 1 | |a Masson-Rouchaud, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Menetrey, Céline |e investigator |4 oth | |
| 700 | 1 | |a Durieu, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Durupt, Stéphane |e investigator |4 oth | |
| 700 | 1 | |a L'Excellent, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Nove-Josserand, Raphaele |e investigator |4 oth | |
| 700 | 1 | |a Ohlmann, Camille |e investigator |4 oth | |
| 700 | 1 | |a Reix, Phillipe |e investigator |4 oth | |
| 700 | 1 | |a Reynaud, Quitterie |e investigator |4 oth | |
| 700 | 1 | |a Werck-Gallois, Marie-Christine |e investigator |4 oth | |
| 700 | 1 | |a Baravalle, Mélissandre |e investigator |4 oth | |
| 700 | 1 | |a Coltey, Bérangère |e investigator |4 oth | |
| 700 | 1 | |a Desmazes-Dufeu, Nadine |e investigator |4 oth | |
| 700 | 1 | |a Dubus, Jean-Christophe |e investigator |4 oth | |
| 700 | 1 | |a Gautier, Clarisse |e investigator |4 oth | |
| 700 | 1 | |a Rey, Jean-Baptiste |e investigator |4 oth | |
| 700 | 1 | |a Reynaud-Gaubert, Martine |e investigator |4 oth | |
| 700 | 1 | |a Stremler, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Caimmi, Davide |e investigator |4 oth | |
| 700 | 1 | |a Chiron, Raphaël |e investigator |4 oth | |
| 700 | 1 | |a Devrait, Margot |e investigator |4 oth | |
| 700 | 1 | |a Moreau, Johan |e investigator |4 oth | |
| 700 | 1 | |a Billon, Yves |e investigator |4 oth | |
| 700 | 1 | |a Blondé, Aurore |e investigator |4 oth | |
| 700 | 1 | |a Guillaumot, Anne |e investigator |4 oth | |
| 700 | 1 | |a Kiefer, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Peretti, Laura |e investigator |4 oth | |
| 700 | 1 | |a Tatopoulos, Aurélie |e investigator |4 oth | |
| 700 | 1 | |a Tiotiu, Angélica |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d 1994 |g 204(2021), 1 vom: 01. Juli, Seite 64-73 |w (DE-627)NLM074657305 |x 1535-4970 |7 nnns |
| 773 | 1 | 8 | |g volume:204 |g year:2021 |g number:1 |g day:01 |g month:07 |g pages:64-73 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1164/rccm.202011-4153OC |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 204 |j 2021 |e 1 |b 01 |c 07 |h 64-73 | ||